Compare Avient Corporation (AVNT) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Avient Corporation vs Zimmer Biomet Holdings Inc — how do they compare? Avient Corporation trades at $44.89 (market cap $4.17B), while Zimmer Biomet Holdings Inc trades at $95.93 (market cap $18.55B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 4.4× Avient Corporation's market cap, and Avient Corporation pays the higher dividend (2.42%). Which is the better fit depends on your goals.
| AVNT | ZBH | |
|---|---|---|
Market Cap | $4.17B | $18.55B |
Sector | Technology | Health |
52-Week High | $45.69 | $107.71 |
52-Week Low | $27.48 | $79.58 |
Enterprise Value | $5.62B | $25.61B |
Dividend Yield | 2.42% | 0.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Avient (AVNT) trades at $44.80, down 1.86% today, with strong technical momentum indicated by bullish moving averages. The company demonstrates solid fundamentals with Q2 2026 EPS of $0.96 beating expectations by $0.07, marking the third consecutive earnings beat. Revenue growth of 5.8% to $917 million in Q2 2026 and improved net income margin of 5.1% reflect operational strength. Analyst consensus remains positive with 60% buy ratings and a $49.00 price target representing 9.4% upside potential.
Avient presents a favorable investment case with consistent earnings outperformance and positive analyst sentiment. The stock offers dividend income with recent $0.28 quarterly payments. Key risks include potential margin pressure from input costs and market volatility. Technical indicators show near-term overbought conditions with RSI at 78.87, suggesting possible consolidation before further upside toward the $49 consensus target.
ZBH trades at $97.78, up 1.27% today, with a bullish technical outlook supported by moving averages and recent earnings beats. The company reported Q2 2026 EPS of $2.07, exceeding expectations, and raised its 2026 outlook. Revenue growth remains steady at 4.8% year-over-year, though net income margin has moderated from 2023 peaks. Analyst consensus is a 'Buy' with a $103.56 price target, indicating modest upside potential from current levels.
The stock offers a balanced risk-reward profile with solid fundamentals and positive momentum, but faces headwinds from margin pressure and rising debt levels. Investors should weigh the strong institutional support and consistent earnings performance against competitive pressures and macroeconomic uncertainties affecting the medtech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Avient Corporation
Avient Corporation is a global leader in specialized and sustainable material solutions. Formed from the legacy of PolyOne and Clariant’s masterbatch business, it provides highly engineered polymer formulations, color systems, and advanced composites that enhance the performance and sustainability of products in industries like healthcare, defense, and consumer packaging.
Read more on AVNT →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
